Cannabidiol - Zynerba Pharmaceuticals
Alternative Names: Cannabidiol gel patch; Cannabidiol transdermal gel; CBD; CBD gel patch; CBD transdermal gel; Synthetic CBD; Topical cannabidiol gel; Topical CBD gel; Transdermal CBD gel; Zygel; ZYN-002Latest Information Update: 13 Oct 2023
At a glance
- Originator Zynerba Pharmaceuticals
- Class Analgesics; Anti-inflammatories; Anti-ischaemics; Antiacnes; Antibacterials; Antiepileptic drugs; Antihyperglycaemics; Antihyperlipidaemics; Antineoplastics; Antiparkinsonians; Antipsoriatics; Antipsychotics; Antirheumatics; Anxiolytics; Behavioural disorder therapies; Cannabinoids; Cardiovascular therapies; Cyclohexenes; Drug withdrawal therapies; Heart failure therapies; Hepatoprotectants; Muscle relaxants; Neuroprotectants; Obesity therapies; Resorcinols; Skin disorder therapies; Small molecules
- Mechanism of Action 5-HT1 serotonin receptor modulators; Antioxidants; Cannabinoid receptor CB1 inverse agonists; Cannabinoid receptor CB2 inverse agonists; Transient receptor potential channel modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase III Fragile X syndrome
- Phase II DiGeorge syndrome; Epilepsy; Pervasive child development disorders
- No development reported Alcoholism; Rheumatoid arthritis; Substance-related disorders
- Discontinued Osteoarthritis
Most Recent Events
- 11 Oct 2023 Zynerba Pharmaceuticals has been acquired by Harmony Biosciences
- 14 Apr 2023 Efficacy and adverse events data from a phase-II CONNECT-FX OLE trial in Fragile X syndrome released by Zynerba Pharmaceuticals
- 06 Apr 2023 Zynerba Pharmaceuticals has patent protection for cannabidiol in Hongkong, Mexico